Literature DB >> 30652553

Distinct Phenotypic Clusters of Glioblastoma Growth and Response Kinetics Predict Survival.

Corbin A Rayfield1, Fillan Grady1, Gustavo De Leon1, Russell Rockne1, Eduardo Carrasco1, Pamela Jackson1, Mayur Vora1, Sandra K Johnston1, Andrea Hawkins-Daarud1, Kamala R Clark-Swanson1, Scott Whitmire1, Mauricio E Gamez1, Alyx Porter1, Leland Hu1, Luis Gonzalez-Cuyar1, Bernard Bendok1, Sujay Vora1, Kristin R Swanson1.   

Abstract

PURPOSE: Despite the intra- and intertumoral heterogeneity seen in glioblastoma multiforme (GBM), there is little definitive data on the underlying cause of the differences in patient survivals. Serial imaging assessment of tumor growth allows quantification of tumor growth kinetics (TGK) measured in terms of changes in the velocity of radial expansion seen on imaging. Because a systematic study of this entire TGK phenotype-growth before treatment and during each treatment to recurrence -has never been coordinately studied in GBMs, we sought to identify whether patients cluster into discrete groups on the basis of their TGK. PATIENTS AND METHODS: From our multi-institutional database, we identified 48 patients who underwent maximally safe resection followed by radiotherapy with imaging follow-up through the time of recurrence. The patients were then clustered into two groups through a k-means algorithm taking as input only the TGK before and during treatment.
RESULTS: There was a significant survival difference between the clusters ( P = .003). Paradoxically, patients among the long-lived cluster had significantly larger tumors at diagnosis ( P = .027) and faster growth before treatment ( P = .003) but demonstrated a better response to adjuvant chemotherapy ( P = .048). A predictive model was built to identify which cluster patients would likely fall into on the basis of information that would be available to clinicians immediately after radiotherapy (accuracy, 90.3%).
CONCLUSION: Dichotomizing the heterogeneity of GBMs into two populations-one faster growing yet more responsive with increased survival and one slower growing yet less responsive with shorter survival-suggests that many patients who receive standard-of-care treatments may get better benefit from select alternative treatments.

Entities:  

Mesh:

Year:  2018        PMID: 30652553      PMCID: PMC6358416          DOI: 10.1200/CCI.17.00080

Source DB:  PubMed          Journal:  JCO Clin Cancer Inform        ISSN: 2473-4276


  32 in total

1.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.

Authors:  Quinn T Ostrom; Haley Gittleman; Peter Liao; Chaturia Rouse; Yanwen Chen; Jacqueline Dowling; Yingli Wolinsky; Carol Kruchko; Jill Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2014-10       Impact factor: 12.300

2.  Brain tumor volume measurement: comparison of manual and semiautomated methods.

Authors:  B N Joe; M B Fukui; C C Meltzer; Q S Huang; R S Day; P J Greer; M E Bozik
Journal:  Radiology       Date:  1999-09       Impact factor: 11.105

3.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1.

Authors:  Roel G W Verhaak; Katherine A Hoadley; Elizabeth Purdom; Victoria Wang; Yuan Qi; Matthew D Wilkerson; C Ryan Miller; Li Ding; Todd Golub; Jill P Mesirov; Gabriele Alexe; Michael Lawrence; Michael O'Kelly; Pablo Tamayo; Barbara A Weir; Stacey Gabriel; Wendy Winckler; Supriya Gupta; Lakshmi Jakkula; Heidi S Feiler; J Graeme Hodgson; C David James; Jann N Sarkaria; Cameron Brennan; Ari Kahn; Paul T Spellman; Richard K Wilson; Terence P Speed; Joe W Gray; Matthew Meyerson; Gad Getz; Charles M Perou; D Neil Hayes
Journal:  Cancer Cell       Date:  2010-01-19       Impact factor: 31.743

4.  Response classification based on a minimal model of glioblastoma growth is prognostic for clinical outcomes and distinguishes progression from pseudoprogression.

Authors:  Maxwell Lewis Neal; Andrew D Trister; Sunyoung Ahn; Anne Baldock; Carly A Bridge; Laura Guyman; Jordan Lange; Rita Sodt; Tyler Cloke; Albert Lai; Timothy F Cloughesy; Maciej M Mrugala; Jason K Rockhill; Russell C Rockne; Kristin R Swanson
Journal:  Cancer Res       Date:  2013-02-11       Impact factor: 12.701

5.  Velocity of radial expansion of contrast-enhancing gliomas and the effectiveness of radiotherapy in individual patients: a proof of principle.

Authors:  K R Swanson; H L P Harpold; D L Peacock; R Rockne; C Pennington; L Kilbride; R Grant; J M Wardlaw; E C Alvord
Journal:  Clin Oncol (R Coll Radiol)       Date:  2008-03-04       Impact factor: 4.126

6.  Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials.

Authors:  Charles Ferté; Marianna Fernandez; Antoine Hollebecque; Serge Koscielny; Antonin Levy; Christophe Massard; Rastislav Balheda; Brian Bot; Carlos Gomez-Roca; Clarisse Dromain; Samy Ammari; Jean-Charles Soria
Journal:  Clin Cancer Res       Date:  2013-11-15       Impact factor: 12.531

7.  Deep sequencing of multiple regions of glial tumors reveals spatial heterogeneity for mutations in clinically relevant genes.

Authors:  Akash Kumar; Evan A Boyle; Mari Tokita; Andrei M Mikheev; Michelle C Sanger; Emily Girard; John R Silber; Luis F Gonzalez-Cuyar; Joseph B Hiatt; Andrew Adey; Choli Lee; Jacob O Kitzman; Donald E Born; Daniel L Silbergeld; James M Olson; Robert C Rostomily; Jay Shendure
Journal:  Genome Biol       Date:  2014-12-03       Impact factor: 13.583

8.  Patient-specific metrics of invasiveness reveal significant prognostic benefit of resection in a predictable subset of gliomas.

Authors:  Anne L Baldock; Sunyoung Ahn; Russell Rockne; Sandra Johnston; Maxwell Neal; David Corwin; Kamala Clark-Swanson; Greg Sterin; Andrew D Trister; Hani Malone; Victoria Ebiana; Adam M Sonabend; Maciej Mrugala; Jason K Rockhill; Daniel L Silbergeld; Albert Lai; Timothy Cloughesy; Guy M McKhann; Jeffrey N Bruce; Robert C Rostomily; Peter Canoll; Kristin R Swanson
Journal:  PLoS One       Date:  2014-10-28       Impact factor: 3.240

9.  Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study.

Authors:  Ji Hyun Lee; Ho Yun Lee; Myung-Ju Ahn; Keunchil Park; Jin Seok Ahn; Jong-Mu Sun; Kyung Soo Lee
Journal:  Cancer Imaging       Date:  2016-03-16       Impact factor: 3.909

10.  From patient-specific mathematical neuro-oncology to precision medicine.

Authors:  A L Baldock; R C Rockne; A D Boone; M L Neal; A Hawkins-Daarud; D M Corwin; C A Bridge; L A Guyman; A D Trister; M M Mrugala; J K Rockhill; K R Swanson
Journal:  Front Oncol       Date:  2013-04-02       Impact factor: 6.244

View more
  9 in total

1.  Novel approaches for glioblastoma treatment: Focus on tumor heterogeneity, treatment resistance, and computational tools.

Authors:  Silvana Valdebenito; Daniela D'Amico; Eliseo Eugenin
Journal:  Cancer Rep (Hoboken)       Date:  2019-11-11

Review 2.  Radiographic Response Assessment Strategies for Early-Phase Brain Trials in Complex Tumor Types and Drug Combinations: from Digital "Flipbooks" to Control Systems Theory.

Authors:  Benjamin M Ellingson; Victor A Levin; Timothy F Cloughesy
Journal:  Neurotherapeutics       Date:  2022-04-22       Impact factor: 7.620

Review 3.  Novel Clinical Trial Designs in Neuro-Oncology.

Authors:  Anurag Saraf; Lorenzo Trippa; Rifaquat Rahman
Journal:  Neurotherapeutics       Date:  2022-08-15       Impact factor: 6.088

4.  Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors.

Authors:  Benjamin M Ellingson; Elizabeth R Gerstner; Andrew B Lassman; Caroline Chung; Howard Colman; Patricia E Cole; David Leung; Joshua E Allen; Manmeet S Ahluwalia; Jerrold Boxerman; Matthew Brown; Jonathan Goldin; Edjah Nduom; Islam Hassan; Mark R Gilbert; Ingo K Mellinghoff; Michael Weller; Susan Chang; David Arons; Clair Meehan; Wendy Selig; Kirk Tanner; W K Alfred Yung; Martin van den Bent; Patrick Y Wen; Timothy F Cloughesy
Journal:  Neuro Oncol       Date:  2022-08-01       Impact factor: 13.029

5.  A Deep Convolutional Neural Network for Annotation of Magnetic Resonance Imaging Sequence Type.

Authors:  Sara Ranjbar; Kyle W Singleton; Pamela R Jackson; Cassandra R Rickertsen; Scott A Whitmire; Kamala R Clark-Swanson; J Ross Mitchell; Kristin R Swanson; Leland S Hu
Journal:  J Digit Imaging       Date:  2020-04       Impact factor: 4.056

Review 6.  Therapeutic Response Assessment of High-Grade Gliomas During Early-Phase Drug Development in the Era of Molecular and Immunotherapies.

Authors:  Benjamin M Ellingson; Patrick Y Wen; Timothy F Cloughesy
Journal:  Cancer J       Date:  2021 Sep-Oct 01       Impact factor: 3.360

7.  Quantifying Uncertainty and Robustness in a Biomathematical Model-Based Patient-Specific Response Metric for Glioblastoma.

Authors:  Andrea Hawkins-Daarud; Sandra K Johnston; Kristin R Swanson
Journal:  JCO Clin Cancer Inform       Date:  2019-02

8.  Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data.

Authors:  Prativa Sahoo; Xin Yang; Daniel Abler; Davide Maestrini; Vikram Adhikarla; David Frankhouser; Heyrim Cho; Vanessa Machuca; Dongrui Wang; Michael Barish; Margarita Gutova; Sergio Branciamore; Christine E Brown; Russell C Rockne
Journal:  J R Soc Interface       Date:  2020-01-15       Impact factor: 4.118

9.  Enhanced Detection of Treatment Effects on Metastatic Colorectal Cancer with Volumetric CT Measurements for Tumor Burden Growth Rate Evaluation.

Authors:  Michael L Maitland; Julia Wilkerson; Sanja Karovic; Binsheng Zhao; Jessica Flynn; Mengxi Zhou; Patrick Hilden; Firas S Ahmed; Laurent Dercle; Chaya S Moskowitz; Ying Tang; Dana E Connors; Stacey J Adam; Gary Kelloff; Mithat Gonen; Tito Fojo; Lawrence H Schwartz; Geoffrey R Oxnard
Journal:  Clin Cancer Res       Date:  2020-09-28       Impact factor: 12.531

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.